|
Market Closed -
OTC Markets
15:58:17 2023-09-07 EDT
|
5-day change | 1st Jan Change | ||
| 120,000.00 USD | -.--% |
|
-20.00% | -20.00% |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index | CI |
| 22-01-20 | Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index | CI |
| Market Cap | 51.95M 45.69M 43.2M 39.19M 73.59M 4.99B 74.02M 517M 200M 2.54B 195M 191M 8.18B | P/E 2019 * |
-
| P/E 2020 | - |
|---|---|---|---|---|---|
| Enterprise Value | -99.99M -87.94M -83.16M -75.43M -142M -9.6B -142M -996M -385M -4.9B -375M -367M -15.74B | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
96% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 week | -20.00% | ||
| Current month | -20.00% | ||
| 1 month | -20.00% | ||
| 3 months | -20.00% | ||
| 6 months | -20.00% | ||
| Current year | -20.00% |
| 3 years | 3,000 |  | 399,160 |
| 5 years | 3,000 | | 399,160 |
| 10 years | 3,000 | | 3,719,992 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Hearne
DFI | Director of Finance/CFO | 63 | 2018-11-18 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/1/21 | EcoR1 Capital, LLC
| Buy | Company | 6,073,551 | 15.7794% | |
| 11/22/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 400,000 | 1.0390% | |
| 11/17/21 | Tavistock Life Sciences Co. (Investment Management)
| Sell | Company | 1,000,000 | 2.5974% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -20.00% | -20.00% | -.--% | 53.25M | |
| +0.11% | +2.76% | +63.52% | +115.51% | 1,055B | |
| +0.27% | +0.73% | +51.33% | +73.10% | 654B | |
| +0.73% | +0.88% | +20.70% | +73.89% | 467B | |
| -1.36% | -0.39% | +40.20% | +41.03% | 348B | |
| +1.34% | +5.47% | +23.37% | +31.30% | 275B | |
| -0.48% | -0.06% | +13.56% | +12.36% | 258B | |
| +0.85% | +8.42% | +53.17% | +55.45% | 224B | |
| +0.85% | +1.40% | +35.78% | +101.47% | 187B | |
| -0.30% | -10.41% | -27.62% | -61.04% | 171B | |
| Average | +0.12% | +0.67% | +25.40% | +44.31% | 363.84B | |
| Weighted average by Cap. | -0.05% | +1.32% | +40.69% | +69.05% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -112M -98.35M -93M -84.35M -158M -10.73B -159M -1.11B -430M -5.48B -420M -411M -17.6B | -126M -111M -105M -95.31M -179M -12.13B -180M -1.26B -486M -6.19B -474M -464M -19.89B |
| Net Debt | -178M -157M -148M -135M -253M -17.12B -254M -1.78B -686M -8.74B -670M -655M -28.08B | -152M -134M -126M -115M -215M -14.58B -216M -1.51B -584M -7.44B -570M -558M -23.92B |
Employees
145
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ODTC Stock
Select your edition
All financial news and data tailored to specific country editions
